Impedimed Share Price and Company Fundamentals



Price
$0.12
Change
-0.005 (-4.000%)
52 week
0.04 - 0.185

Last traded: Today at 6:10 AM

ImpediMed Limited, a medical software technology company, together with its subsidiaries, develops, manufactures, and sells bioimpedance spectroscopy (BIS) devices and software services in Australia, North America, and internationally. It offers SOZO, a noninvasive bioimpedance spectroscopy device for the detection of lymphedema and fluid status monitoring of heart failure patients; SFB7, a single-channel, tetrapolar BIS device to analyze body composition in healthy individuals; and ImpediVET, a single-channel, tetrapolar (BIS) device that measures fluid status and tissue composition for veterinary applications. The company sells its devices to hospitals and clinics. ImpediMed Limited was founded in 1999 and is headquartered in Pinkenba, Australia.

Key Metrics

PE ratio

-

PB ratio

5.22

Dividend yield

Beta

3.00

Market cap

$179M

Enterprise value

$116.2M

Company profile

Primary activitiesThe development and sale internationally of medical devices for diagnosing and monitoring human disorders and diseases.
Industry / SectorMedical Devices / Healthcare
Full time employees69
Websitehttp://www.impedimed.com
Mailing address50 Parker Court Unit 1 Pinkenba QLD 4008 Australia
Phone / Fax61 7 3860 3700 / 61 7 3260 1225
Share registryLINK MARKET SERVICES LIMITED

Dividends

Impedimed does not pay dividends.

Company Executives

As of May 2021, following are the company executives and directors listed on Impedimed.

NameTitleAgeTotal Pay
Mr. Richard CarreonMD, CEO, Pres & Exec. Director716.7k
Mr. David Michae Adams B.Sc., J.D., BScSr. VP of Operations & Strategic Planning460.79k
Mr. Shashi TripathiChief Technology Officer527.59k
Mr. Dennis SchlahtSr. VP of R&D and Technology436.16k
Ms. Catherine KingsfordSr. VP of Medical Affairs349.38k
Mr. Timothy CruickshankChief Financial Officer
Mr. Michael John BassettSr. VP of Corp. & Strategic Devel.
Ms. Nancy T. DeisingerVP of HR
Dr. Frank A. ViciniChief Medical Officer
Ms. Leanne Ralph BBus, ACIS, AAICDCompany Sec.

Profitability and management effectiveness

Profit margin

-291.13%

Operating margin

-354.90%

Return on assets

-51.33%

Return on equity

-87.53%

Profitability ratios are a class of financial metrics that are used to assess a business's ability to generate earnings relative to its revenue, operating costs, balance sheet assets, and shareholders' equity over time, using data from a specific point in time.

The return on equity signifies how well the management is running the company in terms of capital management. The ideal return on equity is greater than 10%. The return on equity is calculated as net income divided by total share holders equity.

Valuation and Trading Info

The market capitalization of Impedimed is 179M and its enterprise value is 116.2M. The enterprise value to revenue ratio of IPD is 17.92.

The IPD's stocks Beta value is 3.00 making it 200% more volatile compared to ASX market index. Technology stocks and small caps tend to have higher betas than the market benchmark. This indicates that adding the stock to a portfolio will increase the portfolio’s risk, but also increase its expected return. On the other hand utility stocks often have low betas because they tend to move more slowly than market averages.

Companies similar to Impedimed (IPD)

Impedimed (ASX:IPD) Frequently Asked Questions

1. What is Impedimed's Stock Symbol?

Impedimed trades on ASX under the ticker symbol "IPD".

2. What is Impedimed's stock price today?

One share of IPD stock can currently be purchased for approximately $0.12.

3. How can I contact Impedimed?

Impedimed's mailing address is 50 Parker Court Unit 1 Pinkenba QLD 4008 Australia. The company can be reached via phone at 61 7 3860 3700.

4. What is Impedimed's official website?

The official website of Impedimed is http://www.impedimed.com.

5. Which share registry manages Impedimed's stock?

Impedimed's stock is managed by LINK MARKET SERVICES LIMITED.